Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
SS-31
EfficacyHigh
Studies8
Participants750
StatusAvailable

SS-31

Elamipretide (D-Arg-Dmt-Lys-Phe-NH2)

SS-31 (Elamipretide) is a mitochondria-targeting tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane to optimize mitochondrial structure and function. Originally developed for mitochondrial diseases and heart failure, SS-31 enhances cellular energy production and reduces oxidative stress across multiple organ systems. It has shown promise in clinical trials for heart failure with preserved ejection fraction, Barth syndrome, and mitochondrial myopathies.

Clinical Safety Profile

Reported Side Effects

Injection site reactions (most common)
Mild headache or fatigue
Nausea or gastrointestinal upset
Dizziness or lightheadedness
Local pain or redness at injection site
Rare allergic reactions
Transient changes in blood pressure

Side Effect Management (Clinical Trial Data)

Injection Site Reactions
Common
18.5%
Headache
Infrequent
8.2%
Nausea
Infrequent
6.7%
Dizziness
Infrequent
5.3%
Fatigue
Infrequent
4.1%

Side Effect Management Strategies

Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise

Clinical Safety Metrics

Variable
Overall Safety Rating
Variable
Discontinuation Rate
Research
Approved Status

CONTRAINDICATIONS

• Known hypersensitivity to SS-31 or components
• Severe active bleeding disorders
• Uncontrolled systemic infections
• Severe hepatic impairment

Medical Disclaimer

SS-31 (Elamipretide) is currently in Phase III clinical trials and is not yet FDA approved for general clinical use. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all investigational uses.